# TOFACITINIB CITRATE
> **ANDA220972** · Abbreviated New Drug Application (Generic) · Sponsor: SCIEGEN PHARMS · Approved 2026-06-25
## Drug
- **FDA Application Number:** ANDA220972
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** TOFACITINIB CITRATE
- **Generic name:** TOFACITINIB CITRATE
- **Active ingredients:** TOFACITINIB CITRATE
- **Dosage form:** TABLET, EXTENDED RELEASE
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** SCIEGEN PHARMS
- **Manufacturer:** ScieGen Pharmaceuticals, INC.
- **First approval:** 2026-06-25
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220972)
---
*MORVS · CC0 1.0*